On May 26, 2026, Newel Health and Gerresheimer announced a powerful strategic collaboration designed to help pharmaceutical and biotech companies build, deploy, and scale next-generation digital health solutions.
By combining Newel Health’s advanced Software as a Medical Device (SaMD) expertise with Gerresheimer’s global leadership in drug delivery and packaging, this partnership offers a complete, plug-and-play digital and device infrastructure for life sciences companies.
Why This Partnership Matters for Pharma
Building a digital and device ecosystem from scratch is incredibly complex. This collaboration eliminates that hurdle, allowing pharma companies to embed digital endpoints, real-world data (RWD), and AI into their clinical development and commercialization efforts seamlessly.
Together, we enable pharma companies to deploy compliant, scalable solutions without having to build or operate the full digital and device infrastructure themselves. — Mithun Ratnakumar, Director, Head of Digitalization & New Business Models at Gerresheimer
Gerresheimer’s expertise in drug delivery, manufacturing, and connected devices, together with Newel Health’s science, H-Core platform, and digital medical devices, will support pharma companies to bring personalized medicine to patients safely and reliably. — Ervin Ukaj, Chief Executive Officer, Newel Health
4 Key Pillars of the Collaboration
The partnership focuses on four major areas to transform patient care and clinical research:
- Designing Digital Endpoints: Utilizing data from connected devices and sensors to continuously and objectively track patient status during clinical trials and post-market care.
- Developing Digital Medical Devices (SaMD): Building tailored monitoring, adherence, and symptom-tracking tools on Newel’s proprietary H-Core platform.
- Unlocking AI-Driven Insights: Merging connected devices and secure data infrastructure to generate high-quality, longitudinal real-world datasets for sponsors.
- Creating Integrated Drug+Device+Digital Solutions: Engineering Gerresheimer’s connected delivery platforms alongside Newel’s AI models and SaMD to deliver a unified, regulatory-grade solution centered around the medicine.
Meet the Partners
About Newel Health
Part of the Future Health Ventures Group, Newel Health designs and operates regulatory-grade digital medical devices. Driven by its H-Core platform, Newel’s portfolio includes Rohkea (a VR-based therapy for chronic pain) and Amicomed (a digital therapeutic for hypertension), alongside a growing pipeline in cardiometabolic disease and neuroscience.
About Gerresheimer
A global partner for the pharma, biotech, and cosmetics industries, Gerresheimer is a leader in pharmaceutical packaging, drug delivery systems, and digital therapy solutions. With over 13,000 employees and 39 production sites worldwide, they ensure safe and reliable drug administration on a global scale.
Moving Beyond Isolated Pilots
By combining forces, Newel Health and Gerresheimer are enabling the pharmaceutical industry to move past small-scale tests and establish truly scalable, repeatable digital assets across multiple therapeutic areas and markets.
